Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, 682041, India.
Department of Neurology, Amrita Institute of Medical Science & Research Centre, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, Kerala, 682041, India.
Neurodegener Dis Manag. 2024;14(3-4):63-67. doi: 10.1080/17582024.2024.2388508. Epub 2024 Aug 19.
Nosocomial infections during immunotherapy pose a dilemma in the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, where a lack of consensus guidelines for this rare disease marks a significant gap in the existing knowledge. This case reports about an 18-year-old female diagnosed with anti-NMDAR encephalitis who was found to be refractory to first- and second-line treatment. During her hospital stay, the patient encountered nearly six episodes of infection, which delayed the use of next-line intervention. It was observed that switching over to the next line of treatment during infections may produce sub-therapeutic outcomes. Thereby, the case highlights the need for de-escalation and appropriate selection of immunosuppression therapy during nosocomial infections and how monotherapy with the patient-tolerated first-line agent can be appropriate during infection.
免疫治疗期间的医院感染给抗 N-甲基-D-天冬氨酸受体(NMDAR)脑炎的治疗带来了困境,这种罕见疾病缺乏共识指南,这是现有知识中的一个重大空白。本病例报告介绍了一位 18 岁女性,被诊断为抗 NMDAR 脑炎,对一线和二线治疗均无反应。在住院期间,患者遭遇了近六次感染,这延迟了二线干预的使用。观察到在感染期间转换至下一线治疗可能产生低于治疗效果。因此,该病例强调了在医院感染期间需要降级和适当选择免疫抑制治疗,以及在感染期间使用患者耐受的一线药物单药治疗可能是合适的。